Prostate cancer treatment and diagnostics abroad

Prostate cancer is a malignancy of the prostate gland, most often an adenocarcinoma. Its behaviour varies: some tumours may be suitable for planned specialist monitoring, while others require treatment because of their risk or spread. An elevated prostate-specific antigen, or PSA, result does not diagnose cancer. Benign prostate enlargement and inflammation can also increase PSA, and urinary symptoms may have causes unrelated to cancer.

Assessment may combine a review of PSA results, examination, prostate MRI and a biopsy when indicated. After diagnosis, the tissue grade, extent of disease, PSA and overall health help guide decisions. Eligible patients may consider active surveillance; others may need surgery, radiotherapy or systemic treatment. There is no single best approach for everyone. Before a consultation, collect previous results and discuss your priorities, including urinary control, sexual function, fertility and quality of life. Ask how treatment benefits, harms and follow-up apply to your situation.

From an abnormal result to a diagnosis

A PSA result is one part of assessment, not proof of cancer. The clinician considers previous values, symptoms, medicines, examination and relevant risk factors. Decisions about screening before symptoms appear should include a discussion of benefits and harms, rather than a blanket recommendation for everyone.

MRI can help assess the prostate and guide a biopsy decision, but does not by itself establish or exclude every cancer. Diagnosis usually requires examination of prostate tissue. A biopsy report describes the tumour and its grade, often using a Grade Group and Gleason score. Grade reflects how the cells look; stage describes the extent of disease.

Matching care to risk and health

A team involving urology and oncology reviews pathology, PSA, staging and personal circumstances. Additional imaging is selected according to risk and the question being asked. PSMA PET imaging is useful in certain situations but is not required for every patient.

Active surveillance is an option for eligible patients, particularly with low-risk localised disease. It uses planned reassessment and retains the possibility of treatment if relevant changes occur. It differs from watchful waiting, which usually focuses on symptoms when curative treatment is not intended. Neither approach should mean losing contact with the care team.

Treatment choices and possible effects

Localised cancer may be treated with surgery or radiotherapy, with hormone treatment added in selected settings. Advanced disease may need hormone-based combinations, chemotherapy or other systemic treatments chosen for its features and previous therapy. Molecular testing can guide particular treatment decisions when appropriate.

Discuss urinary leakage, erection problems, bowel effects and the possible impact on fertility. Hormone treatment has its own effects, including on bone and metabolic health. A robotic operation or a named radiation technique does not guarantee cancer control or preserved function. Ask why the proposed approach fits your disease and what alternatives remain.

Preparing for continuing care

Bring biopsy reports, MRI images, PSA history and a medicine list. Agree who will review follow-up tests and new symptoms. PSA monitoring after treatment is interpreted differently according to the treatment received; an isolated number should not be used to change therapy without clinical review.

Frequently asked questions

Does a high PSA mean cancer?

No. Several benign conditions can raise it. Further assessment depends on the full clinical picture.

Does everyone need immediate treatment?

No. Active surveillance may be suitable for selected patients, with a structured review plan.

Is surgery always the best option?

No. Disease risk, health, alternatives and personal priorities guide shared decisions.

Can outcomes be predicted from stage alone?

No. Pathology and other factors matter. Your team can explain the uncertainty and the purpose of each treatment.